# US 2026/0085108 A1 · Methods of separating chelator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085108 A1
- Document ID: US20260085108A1
- Status: Published application
- Kind: A1
- Application number: 19/109,768
- Filed: 2023-09-08
- Published: 2026-03-26
- Earliest claimed: 2022-09-09
- Applicants: Bristol-Myers Squibb Company
- Inventors: Jason HUANG; Qiang LI
- Web page: https://patentgrep.com/patent/US20260085108A1

## CPC

- B01D 15/363: {Anion-exchange}
- B01D 15/14: relating to the introduction of the feed to the apparatus
- B01D 15/305: {Hydrophilic interaction chromatography [HILIC]}
- B01D 15/327: {with hydrophobic interaction}
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B01D 15/3847: {Multimodal interactions}
- B01D 15/424: {Elution mode}
- C07K 1/165: {mixed-mode chromatography}
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G01N 30/16: Injection (G01N30/24 takes precedence)
- G01N 30/52: Physical parameters
- G01N 30/74: Optical detectors {(measurement of intensity, velocity, spectral content, polarisation, or phase of infrared, visible or ultraviolet light G01J)}
- G01N 2030/027: {Liquid chromatography}
- G01N 2030/525: {surface properties, e.g. porosity}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure is directed to methods of separating a chelator from a mixture and measuring the concentration of the chelator in the mixture using a chromatography column. Such methods can be useful in adjusting the concentration of a chelator of a composition comprising a protein.

## Claims

### Claim 1

A method of separating a chelator in a mixture comprising a protein and the chelator, the method comprising contacting the mixture with a chromatography column, wherein the chromatography column comprises a stationary phase, wherein the stationary phase:
has a charge, which is the same as the charge of the protein,
is capable of forming a non-polar interaction with the chelator, and
comprises a porous surface with a pore size that is less than the diameter of the protein.

### Claim 2 (depends on 1)

The method of claim 1, which further comprises contacting the chromatography column with an elution buffer, wherein the contacting with the elution buffer occurs after the contacting of the chromatography column with the mixture.

### Claim 3 (depends on 2)

The method of claim 2, wherein after contacting the chromatography column with the elution buffer, the protein is selectively eluted from the chromatography column while the chelator is retained within the chromatography column.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, further comprising eluting the chelator from the chromatography column.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, further comprising measuring the concentration of the chelator in the mixture

### Claim 6 (depends on 5)

The method of claim 5, wherein measuring the concentration of the chelator in the mixture comprises contacting a standard solution with the chromatography column, wherein the standard solution comprises the chelator.

### Claim 7 (depends on 6)

The method of claim 6, wherein the standard is retained within the chromatography column for at least about 3.5 min.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein the standard is retained in the column for about 3.5 min, for about 3.6 min, for about 3.7 min, for about 3.8 min, for about 3.9 min, for about 4.0 min, or for about 4.1 min.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1 to 8, wherein the contacting of the mixture with the chromatography column comprises directly injecting the mixture into the chromatography column.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein, prior to the contacting of the mixture with the chromatography column, the mixture is diluted in a dilution buffer.

### Claim 11 (depends on 10)

The method of claim 10, wherein the mixture is diluted in the dilution buffer at about 1:1 dilution, at about 1:2 dilution, at about 1:3 dilution, at about 1:4 dilution, at about 1:5 dilution, at about 1:6 dilution, at about 1:7 dilution, at about 1:8 dilution, at about 1:9 dilution, at about 1:10 dilution, or at about 1:20 dilution, at about 1:30 dilution, at about 1:40 dilution, at about 1:50 dilution, at about 1:60 dilution, at about 1:70 dilution, at about 1:80 dilution, at about 1:90 dilution, at about 1:100 dilution, at about 1:200 dilution, at about 1:300 dilution, at about 1:400 dilution, or at about 1:500 dilution.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, which further comprises (i) obtaining a peak response from the mixture (ru), (ii) obtaining a peak response from the standard solution (rs), (iii) or both (i) and (ii), wherein the peak response is the peak area as determined by high performance liquid chromatography (“HPLC”) or ultra performance liquid chromatography (“UPLC”) at a wavelength of 260 nm.

### Claim 13 (depends on 12)

The method of claim 12, wherein the ru and the rs are obtained by HPLC or UPLC.

### Claim 14 (depends on 10, 11, 12, 13)

The method of any one of claims 10 to 13, wherein the concentration (μg/mL) of the chelator is calculated as formula (I):
C
⁢
(
V
u
/
V
n
)
⁢
(
r
u
/
r
s
)
wherein C is the concentration (μg/mL) of the chelator in the standard solution; ru and rs are the peak responses obtained from the mixture and the standard solution, respectively, Vu is the total volume (μL) of the mixture after being diluted; Vn is the volume (μL) of the mixture before the dilution,
wherein C is calculated as formula (II):
[
W
s
×
P
]
×
D
×
1000
/
V
s
wherein Ws is the weight (mg) of a reference material for the chelator, P is the purity of the reference material (expressed as a fraction), Vs is the volume of the standard solution (mL), and D is the Dilution Factor (1/100).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of adjusting the concentration of a chelator in a composition comprising a protein, the method comprising measuring the concentration of the chelator present in the composition, wherein the concentration of the chelator present in the composition is measured according to the method of any one of claims 1 to 14.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of producing a composition comprising a protein, the method comprising measuring a concentration of a chelator present in the composition, wherein the concentration of the chelator present in the composition is measured according to the method of any one of claims 1 to 14.

### Claim 17 (depends on 15, 16)

The method of claim 15 or 16, which comprises increasing the concentration of the chelator if the measured concentration of the chelator is less than a reference amount (e.g., the concentration of the chelator present in a standard solution).

### Claim 18 (depends on 17)

The method of claim 17, wherein the measured concentration of the chelator is less than about 5%, less than about 10%, less than about 20%, less than about 30%, less than about 40%, less than about 50%, less than about 60%, less than about 70%, less than about 80%, less than about 90%, or about 100% as compared to the reference amount.

### Claim 19 (depends on 17, 18)

The method of claim 17 or 18, wherein increasing the concentration of the chelator comprises adding an amount of the chelator to the composition.

### Claim 20 (depends on 19)

The method of claim 19, which further comprises an additional measuring of the concentration of the chelator present in the composition after adding the amount of the chelator to the composition.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 20)

The method of claim 20, wherein the additional measuring is performed according to the method of any one of claims 1 to 14.

### Claim 22 (depends on 19, 20, 21)

The method of any one of claims 19 to 21, wherein after adding the amount of the chelator to the composition, the concentration of the chelator present in the composition is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% as compared to the reference.

### Claim 23 (depends on 15, 16)

The method of claim 15 or 16, which comprises decreasing the concentration of the chelator if the measured concentration of the chelator is higher than the reference amount.

### Claim 24 (depends on 23)

The method of claim 23, wherein the measured concentration of the chelator is greater than about 5%, greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, greater than about 125%, greater than about 150%, greater than about 175%, or greater than about 200% as compared to the reference amount.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein decreasing the concentration of the chelator comprises adding a diluent to the composition, increasing the concentration of the protein in the composition, or both.

### Claim 26 (depends on 25)

The method of claim 25, which further comprises an additional measuring of the concentration of the chelator present in the composition after the decreasing.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 26)

The method of claim 26, wherein the additional measuring is performed according to the method of any one of claims 1 to 14.

### Claim 28 (depends on 23, 24, 25, 26, 27)

The method of any one of claims 23 to 27, wherein after the decreasing, the concentration of the chelator present in the composition is at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% as compared to the reference.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1 to 28, wherein the chromatography column and the protein have positive charge.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1 to 29, wherein the chromatography column is capable of eluting a protein, wherein the diameter of the protein is less than about 70 Å, less than about 80 Å, less than about 90 Å, less than about 100 Å, less than about 110 Å, less than about 120 Å, less than about 130 Å, less than about 140 Å, less than about 150 Å, less than about 160 Å, less than about 170 Å, or less than about 180 Å.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein the chromatography column is capable of eluting a protein, wherein the diameter of the protein is between about 70 Å and about 180 Å, about between 70 Å and about 170 Å, between about 70 Å and about 160 Å, between about 70 Å and about 150 Å, between 70 about Å and about 140 Å, between about 70 Å and about 130 Å, between about 70 Å and about 120 Å, between about 70 Å and about 110 Å, between about 70 Å and about 100 Å, between about 80 Å and about 180 Å, between about 80 Å and about 170 Å, between about 80 Å and about 160 Å, between about 80 Å and about 150 Å, between about 80 Å and about 140 Å, between about 80 Å and about 130 Å, between about 80 Å and about 120 Å, between about 80 Å and about 110 Å, between about 80 Å and about 100 Å, between about 90 Å and about 180 Å, between about 90 Å and about 170 Å, between about 90 Å and about 160 Å, between about 90 Å and about 150 Å, between about 90 Å and about 140 Å, between about 90 Å and about 130 Å, between about 90 Å and about 120 Å, between about 90 Å and about 110 Å, between about 90 Å and about 100 Å, between about 100 Å and about 180 Å, between about 100 Å and about 170 Å, between about 100 Å and about 160 Å, between about 100 Å and about 150 Å, between about 100 Å and about 140 Å, between about 100 Å and about 130 Å, between about 100 Å and about 120 Å, between about 100 Å and about 110 Å, between about 110 Å and about 180 Å, between about 110 Å and about 170 Å, between about 110 Å and about 160 Å, between about 110 Å and about 150 Å, between about 110 Å and about 140 Å, between about 110 Å and about 130 Å, between about 110 Å and about 120 Å, between about 120 Å and about 180 Å, between about 120 Å and about 170 Å, between about 120 Å and about 160 Å, between about 120 Å and about 150 Å, between about 120 Å and about 140 Å, between about 120 Å and about 130 Å, between about 130 Å and about 180 Å, between about 130 Å and about 170 Å, between about 130 Å and about 160 Å, between about 130 Å and about 150 Å, between about 130 Å and about 140 Å, between about 140 Å and about 180 Å, between about 140 Å and about 170 Å, between about 140 Å and about 160 Å, between about 140 Å and about 150 Å, between about 150 Å and about 180 Å, between about 150 Å and about 170 Å, between about 150 Å and about 160 Å, between about 160 Å and about 180 Å, between about 160 Å and about 170 Å, or between about 170 Å and about 180 Å.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1 to 31, wherein the pore size is no more than about 110 Å.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, wherein the pore size is about 110 Å, about 100 Å, about 90 Å, about 80 Å, or about 70 Å.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1 to 33, wherein the chelator comprises DTPA, EDTA, or both.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1 to 34, wherein the chromatography column is an hydrophilic interaction chromatography (HILIC) column.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1 to 35, wherein the chromatography column is packed with a stationary phase comprising multimode hydrophobic ligand and a positive charged terminal functional group.

### Claim 37 (depends on 36)

The method of claim 36, wherein the positive charged terminal functional group comprises an amino group.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1 to 37, wherein the column is Newcrom BH column.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1 to 38, wherein the chromatography is performed using a mobile phase comprising a buffer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the buffer comprises acetonitrile, sulfuric acid, FeCl3, or a combination thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the acetonitrile is present in the buffer at a concentration of about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, or about 3%.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the sulfuric acid is present in the buffer at a concentration of about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1%.

### Claim 43 (depends on 42)

The method of claim 42, wherein the sulfuric acid is present in the buffer at a concentration of about 0.15% to 0.20%.

### Claim 44 (depends on 40, 41, 42, 43)

The method of any one of claims 40 to 43, wherein the FeCl3 is present in the buffer at a concentration of about 0.1 mM, about 0.2 mM, about 0.3 mM, about 0.4 mM, about 0.5 mM, about 0.6 mM, about 0.7 mM, about 0.8 mM, about 0.9 mM, or about 1.0 mM.

### Claim 45 (depends on 40, 41, 42, 43, 44)

The method of any one of claims 40 to 44, wherein the buffer comprises 2% Acetonitrile, 0.2% sulfuric acid, and 0.6 mM FeCl3.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43 to 45, wherein the buffer comprises 2% Acetonitrile, 0.15% sulfuric acid, 0.6 mM FeCl3.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 39 to 46, wherein the buffer has a pH from about 1.0 to about 5.0, or 1.0 to about 4.5, or about 1.0 to about 4.0.

### Claim 48 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 39 to 47, wherein the buffer has a pH of about 0.5, about 1.0, about 1.5, about 2.0, about 2.5, about 3.0, about 3.5, about 4.0, about 4.5, or about 5.0.

### Claim 49 (depends on 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 39 to 48, wherein the buffer has a pH of about 1.0 to about 4.0, or any pH in between.

### Claim 50 (depends on 10, 11, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of claim 10 or 11, wherein the dilution buffer is the buffer of any one of claims 39-49.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 1 to 50, wherein the concentration of the protein in the mixture is about 30 mg/mL, about 40 mg/mL, about 50 mg/mL, about 60 mg/mL, about 70 mg/mL, about 80 mg/mL, about 90 mg/mL, about 100 mg/mL, about 110 mg/mL, about 120 mg/mL, about 130 mg/mL, about 140 mg/mL, about 150 mg/mL, about 160 mg/mL, about 170 mg/mL, about 180 mg/mL, about 190 mg/mL, about 200 mg/mL, about 210 mg/mL, about 220 mg/mL, about 230 mg/mL, about 240 mg/mL, about 250 mg/mL, about 260 mg/mL, about 270 mg/mL, about 280 mg/mL, about 290 mg/mL, or about 300 mg/mL.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1 to 51, wherein the protein is conjugated to a drug, such that the mixture or the composition comprises a protein-drug conjugate (PDC).

### Claim 53 (depends on 52)

The method of claim 52, wherein the protein-drug conjugate comprises an antibody-drug conjugate (ADC).

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1 to 53, wherein the protein comprises an antibody or antigen binding portion thereof.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1 to 51, wherein the protein comprises a fusion protein.

### Claim 56 (depends on 55)

The method of claim 55, wherein the fusion protein comprises a half-life extending moiety.

### Claim 57 (depends on 56)

The method of claim 56, wherein the half-life extending moiety comprises an Fc.

### Claim 58 (depends on 57)

The method of claim 57, wherein the fusion protein comprises an Fc fused to an antibody or antigen binding portion thereof.

### Claim 59 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

A composition produced according to the method of any one of claims 16 to 58.

### Claim 60 (depends on 59)

The composition of claim 59, which further comprises a pharmaceutically acceptable excipient.
